Serlopitant

Chemical compound

None

Identifiers

IUPAC name

3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-2H-isoindol-2-yl]cyclopent-2-en-1-one

CAS Number

860642-69-9

PubChem CID

23653789

ChemSpider

24686685

UNII

277V92K32B

KEGG

D09378

ChEMBL

ChEMBL447955

CompTox Dashboard (EPA)

DTXSID701006599

Chemical and physical dataFormulaC₂₉H₂₈F₇NO₂Molar mass555.537 g·mol⁻¹3D model (JSmol)

Interactive image

SMILES

C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@H]2CC[C@@H]3CN(C[C@H]3[C@@H]2C4=CC=C(C=C4)F)C5=CC(=O)CC5

InChI

InChI=1S/C29H28F7NO2/c1-16(19-10-20(28(31,32)33)12-21(11-19)29(34,35)36)39-26-9-4-18-14-37(23-7-8-24(38)13-23)15-25(18)27(26)17-2-5-22(30)6-3-17/h2-3,5-6,10-13,16,18,25-27H,4,7-9,14-15H2,1H3/t16-,18-,25-,26+,27+/m1/s1
Key:FLNYCRJBCNNHRH-OIYLJQICSA-N

Serlopitant (INN,^[1] codenamed VPD-737) is a drug which acts as an NK₁ receptor antagonist. It was assessed in clinical trials for the treatment of urinary incontinence and overactive bladder, but while it was superior to placebo it provided no advantage over existing approved drugs, and was not approved for further development for this indication.^[2]^[3] Serlopitant is now undergoing clinical trials for the treatment of chronic pruritus (itch)^[4]

References

^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 62" (PDF). World Health Organization. 2009. pp. 261–2. Retrieved 17 November 2016.
^ Frenkl TL, Zhu H, Reiss T, Seltzer O, Rosenberg E, Green S (August 2010). "A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder". The Journal of Urology. 184 (2): 616–22. doi:10.1016/j.juro.2010.03.147. PMID 20639026.
^ Payton S (August 2010). "Urinary incontinence: Neurokinin receptor antagonist inferior to tolterodine for OAB". Nature Reviews. Urology. 7 (8): 418. doi:10.1038/nrurol.2010.105. PMID 20726068. S2CID 33202979.
^ "For Irritating Itch, a Promising Option Under Scrutiny".